To include your compound in the COVID-19 Resource Center, submit it here.

DLX105 topical: Phase II data

A double-blind, placebo-controlled, Austrian and German Phase II trial in 59 patients with mild to moderate plaque psoriasis showed twice-daily topical 0.5% DLx10 5 for 4 weeks

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE